🇺🇸 FDA

Intelligence Platform

Patents

Browse 134 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9238692

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9238042

Antisense modulation of interleukins 17 and 23 signaling

Sarepta Therapeutics, Inc. · Granted Tue Jan 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9173880

Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9084761

Use of interleukin-15 to treat cardiovascular diseases

THE UNITED STATES OF AMERICA REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS · Granted Tue Jul 21 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 16 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9045559

Method for screening inhibitors of interleukin-32 (IL-32)

The Regents of the University of Colorado · Granted Tue Jun 02 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 28 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8962814

Interleukin-1α antibodies and methods of use

XBIOTECH INC. · Granted Tue Feb 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8945559

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8603456

Method of treating hair loss with compositions containing interleukin-1

United Technologies UT AG · Granted Tue Dec 10 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8556882

Inducible interleukin-12

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8388969

Interleukin-1 alpha antibodies and methods of use

XBIOTECH INC. · Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8388956

Interleukin-1 alpha antibodies and methods of use

XBIOTECH INC. · Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8323635

Methods of using interleukin-1 receptor antagonist as a myeloprotective agent

GENERAL REGENERATIVES, LTD. · Granted Tue Dec 04 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8298523

Compositions containing interleukin-1 and peptides

United Technologies UT AG · Granted Tue Oct 30 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8133915

Interleukin-1 and tumor necrosis factor-α modulators; syntheses of such modulators and met

The Regents of the University of California · Granted Tue Mar 13 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8119631

Inhibitors of interleukin-1β converting enzyme

Vertex Pharmaceuticals Incorporated · Granted Tue Feb 21 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8067390

Therapeutic targeting of interleukins using siRNA in neutral liposomes

The Board of Regents of the University of Texas System · Granted Tue Nov 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8034337

Interleukin-1α antibodies

XBIOTECH INC. · Granted Tue Oct 11 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 06 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7981409

Method of reducing aging of skin by applying interleukin-1 alpha

United Technologies UT AG · Granted Tue Jul 19 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 14 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7893299

Interleukin-1 and tumor necrosis factor-αmodulators; syntheses of such modulators and meth

The Regents of the University of California · Granted Tue Feb 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7790713

Inhibitors of interleukin-1β converting enzyme

Vertex Pharmaceuticals Incorporated · Granted Tue Sep 07 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 02 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7772366

Inhibitors of interleukin-1β converting enzyme

Vertex Pharmaceuticals Incorporated · Granted Tue Aug 10 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 05 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7449201

Storage stable power compositions of interleukin-4 receptor

Nektar Therapeutics · Granted Tue Nov 11 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 06 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7381405

Methods of preparing lymphocytes that express interleukin-2 and their use in the treatment

The United States of America, as represented by the Department of Health and Human Services · Granted Tue Jun 03 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7288671

Interleukin-1 and tumor necrosis factor-α modulators, synthesis of said modulators and the

The Regents of the University of California · Granted Tue Oct 30 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

granted